From the publishers of JADPRO

Biomarkers in NSCLC Resource Center

Advertisement

Interview With Ivy Elkins on the Patient Experience in NSCLC

Interview With Andrew Lerner, MD, on Biomarker Testing

Interview With Beth Sandy, MSN, CRNP, OCN®, on KRAS Mutations

Welcome to the Biomarkers in NSCLC Resource Center! Here you will find updated information, education, and other resources from the field of non-small cell lung cancer. We're excited to provide this offering to you and your colleagues. Take a look around, and send us your feedback to jadpro-editor@conexiant.com

Rasheda Persinger, NP-C, Medical Oncology Lead Nurse Practitioner, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital

KRAS G12C Biomarker Testing & Analysis

NSCLC Biomarker Fact Sheet for KRAS G12C

Decision Making Criteria in Oncology

CAP/IASLC/AMP Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

Molecular Testing Strategies in Non-small Cell Lung Cancer: Optimizing the Diagnostic Journey

ESMO Open

Postmarketing Safety of Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Analysis of the FDA Adverse Event Reporting System (FAERS)

Journal of Thoracic Oncology

Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC

American Society of Clinical Oncology Educational Book

Biomarker Testing for Patients With Advanced Non–Small Cell Lung Cancer: Real-World Issues and Tough Choices

The ASCO Post

FDA Approves Neoadjuvant Nivolumab and Platinum Doublet Chemotherapy for Early-Stage NSCLC

Journal of Clinical Oncology

Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion

Future Medicine

Diagnostic and Economic Value of Biomarker Testing for Targetable Mutations in Non-Small-Cell Lung Cancer: A Literature Review

Cancers

Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience

The ASCO Post

Julia Rotow, MD, on Patient Selection in Treating Thoracic Cancers: Looking to Driver Mutations and Biomarkers

Cancer Medicine

Defining Comprehensive Biomarker-Related Testing and Treatment Practices for Advanced Non-Small-Cell Lung Cancer: Results of a Survey of U.S. Oncologists

Journal of Clinical Oncology

Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment

Fast Facts #12: Choosing/Sequencing Therapy